OBJECTIVE: Variation in prescription of psychotropic medications to patients with schizophrenia spectrum disorders may underlie health inequities. Using a national U.S. Medicaid sample, the authors examined prescription patterns of psychotropic medications commonly used for managing schizophrenia. METHODS: Data from the 2011-2012 Medicaid Analytic eXtract were examined for demographic predictors of and variation across states in psychotropic medication prescription among adult patients diagnosed as having schizophrenia spectrum disorders (N=357,914). Percentages of patients in each state who filled prescriptions of at least 15 days of any antipsychotic, clozapine, antidepressant, benzodiazepine, mood stabilizer, or long-acting injectable (LAI) antipsychotic medication were determined after adjustment for demographic and clinical covariates. Multivariate regressions of clinical and demographic factors predicting prescription patterns were conducted. RESULTS: Prescribing patterns for all types of psychotropic medications varied across states. Clozapine and LAI prescriptions showed the most dramatic differences across states and among patients with different demographic characteristics. Across states, adjusted proportions of prescriptions ranged from 4% to 22% for LAIs and from 1% to 11% for clozapine. Non-Hispanic Blacks and people of other race-ethnicities were more likely than non-Hispanic Whites to fill prescriptions for LAIs, and non-Hispanic Whites were more likely than individuals from other racial-ethnic groups to fill prescriptions for clozapine and all other medications. CONCLUSIONS: Considerable variation in prescribing patterns of LAIs and clozapine by race-ethnicity and across states suggests uneven quality of care for individuals with schizophrenia spectrum disorders in the United States. A better understanding of what causes this variation could inform policy makers to improve treatment for this vulnerable population.
OBJECTIVE: Variation in prescription of psychotropic medications to patients with schizophrenia spectrum disorders may underlie health inequities. Using a national U.S. Medicaid sample, the authors examined prescription patterns of psychotropic medications commonly used for managing schizophrenia. METHODS: Data from the 2011-2012 Medicaid Analytic eXtract were examined for demographic predictors of and variation across states in psychotropic medication prescription among adult patients diagnosed as having schizophrenia spectrum disorders (N=357,914). Percentages of patients in each state who filled prescriptions of at least 15 days of any antipsychotic, clozapine, antidepressant, benzodiazepine, mood stabilizer, or long-acting injectable (LAI) antipsychotic medication were determined after adjustment for demographic and clinical covariates. Multivariate regressions of clinical and demographic factors predicting prescription patterns were conducted. RESULTS: Prescribing patterns for all types of psychotropic medications varied across states. Clozapine and LAI prescriptions showed the most dramatic differences across states and among patients with different demographic characteristics. Across states, adjusted proportions of prescriptions ranged from 4% to 22% for LAIs and from 1% to 11% for clozapine. Non-Hispanic Blacks and people of other race-ethnicities were more likely than non-Hispanic Whites to fill prescriptions for LAIs, and non-Hispanic Whites were more likely than individuals from other racial-ethnic groups to fill prescriptions for clozapine and all other medications. CONCLUSIONS: Considerable variation in prescribing patterns of LAIs and clozapine by race-ethnicity and across states suggests uneven quality of care for individuals with schizophrenia spectrum disorders in the United States. A better understanding of what causes this variation could inform policy makers to improve treatment for this vulnerable population.
Entities:
Keywords:
Antipsychotics; Drug treatment; Psychopharmacology; Psychotropic medication; Schizophrenia
Authors: Joyce C West; Steven C Marcus; Joshua Wilk; Lisa M Countis; Darrel A Regier; Mark Olfson Journal: Schizophr Bull Date: 2007-12-18 Impact factor: 9.306
Authors: George A Keepers; Laura J Fochtmann; Joan M Anzia; Sheldon Benjamin; Jeffrey M Lyness; Ramin Mojtabai; Mark Servis; Art Walaszek; Peter Buckley; Mark F Lenzenweger; Alexander S Young; Amanda Degenhardt; Seung-Hee Hong Journal: Focus (Am Psychiatr Publ) Date: 2020-11-05
Authors: Christoph U Correll; Leslie Citrome; Peter M Haddad; John Lauriello; Mark Olfson; Stephen M Calloway; John M Kane Journal: J Clin Psychiatry Date: 2016 Impact factor: 4.384
Authors: Christoph U Correll; Jose M Rubio; Gabriella Inczedy-Farkas; Michael L Birnbaum; John M Kane; Stefan Leucht Journal: JAMA Psychiatry Date: 2017-07-01 Impact factor: 21.596
Authors: Herbert Y Meltzer; Larry Alphs; Alan I Green; A Carlo Altamura; Ravi Anand; Alberto Bertoldi; Marc Bourgeois; Guy Chouinard; M Zahur Islam; John Kane; Ranga Krishnan; J P Lindenmayer; Steven Potkin Journal: Arch Gen Psychiatry Date: 2003-01
Authors: T Scott Stroup; Tobias Gerhard; Stephen Crystal; Cecilia Huang; Zhiqiang Tan; Melanie M Wall; Chacku M Mathai; Mark Olfson Journal: Psychiatr Serv Date: 2018-04-02 Impact factor: 3.084
Authors: Kimberly Eaton Hoagwood; Susan Essock; Joseph Morrissey; Anne Libby; Sheila Donahue; Benjamin Druss; Molly Finnerty; Linda Frisman; Meera Narasimhan; Bradley D Stein; Jennifer Wisdom; Judy Zerzan Journal: Adm Policy Ment Health Date: 2016-01
Authors: Stephan Reymann; Georgios Schoretsanitis; Stephan T Egger; Alexey Mohonko; Matthias Kirschner; Stefan Vetter; Philipp Homan; Erich Seifritz; Achim Burrer Journal: J Pers Med Date: 2022-03-11